Skip to main content

Vaxil Bio: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (VXL)

The Globe and Mail - Tue Nov 29, 2022
Sector

Vaxil Bio is now ranked among the top 10 undervalued stocks in the Healthcare sector on the TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below). The healthcare sector contains companies in biotechnology, pharmaceuticals, hospitals, home and long-term care as well as related medical equipment manufacturers and suppliers.

All data provided as-at market close November 27, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Vaxil Bio Vaxil Bio Ltd is an immuno-oncology biotechnology company. The company is focused on developing novel immunotherapies including neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. Vaxil Bio is listed under VXL on the TSX Venture Exchange.

Symbol

Name

Close Price

Shares Outstanding

P/E

P/B

Cash per Share

Net Cash per Share

VXL-XVaxil Bio0.0100000
MNOW-XMednow0.2700000
JUMP-XLeveljump Healthcare0.0700000
IBO-XUniversal Ibogaine0.0300000
NLTA-XEnlighta0.0700000
KNE-XKane Biotech0.0800000
NLH-XNova Leap Health0.2700000
ACST-XAcasti Pharma0.5600000
THNK-XThink Research0.3200000
ROMJ-XRubicon Organics0.6400000

More about Vaxil Bio

Stocks in this category are held primarily for capital appreciation.

Artificial intelligence at Report on Business

Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.